COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) (South African variant 501Y.V2 ineage,B.1.351) Spike Protein RBD(K417N, E484K and N501Y mutant)

Cat No.: GMP-V-2019nCoV-Smu-003

Order information

Package Catalog No. Price(In USD) Qty (Quantity) Sum(In USD)
1mg GMP-V-2019nCoV-Smu-003-1mg 5990
10mg GMP-V-2019nCoV-Smu-003-10mg 38790
100mg GMP-V-2019nCoV-Smu-003-100mg 258000
≥100mg GMP-V-2019nCoV-Smu-003-xmg Inquiry
Shipping Cost: 760.00
Total:



Description

Accession Number QHD43415.1
Expression platform 2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
IsotypesMamamlian (human cell)
TagC-His
Products descriptionRecombinant 2019-nCoV(SARS-CoV-2)-South African variant 501Y.V2 lineage(B.1.351),B.1.351 receptor binding domain (RBD) from the Spike Protein (S protein) with K417N, E484K and N501Y mutation was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus.
Bioactivity validation ACE2 binding;
Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
PurityPurity: ≥95% (SDS-PAGE)
ApplicationSpike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.
Immunogen in Elisa,lateral-flow tests,and other immunoassays;
Standard substance
The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass35kDa
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2) (South African variant 501Y.V2 lineage(B.1.351), B.1.351) Spike Protein RBD(K417N, E484K and N501Y mutant)

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19vaccines and therapeutic antibodies.



Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -South African variant 501Y.V2 lineage(B.1.351), B.1.351

The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV) lineage (501Y.V2, B.1.351), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces of South Africa.

Mutations of Spike protein in SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351) (B.1.351)spread in South Africa

Three of the spike mutations are at key residues in the RBD (N501Y, E484K and K417N), three are in the N-terminal domain (L18F, D80A and D215G) and one is in loop 2 (A701V). Deletion of three amino acids at L242-244L is disputed with a L242H mutation1.

Spike Mutation in SARS-COV-2
(2019nCOV) 501Y.V2 lineage(B.1.351)
Spike-S1 Subunit
N Terminal
L18F
D8OA
D215G
Spike-S1 Subunit L242-244 deletion disputed with a L242H mutation
Spike-S1 Subunit R246I
Spike-RBD K417N Important residues mutation
E484K
N501Y
Spike-S1 Subunit D614G A popular mutation in different new SARS-CoV-2 lineage
Spike-S2 Subunit A701V
Picture loading failed.
Figure. Amino acid changes in the spike region of the 190 S501Y.V2 genomes1

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351)

SARS-COV-2 (2019nCOV) -South African variant 501Y.V2 lineage(B.1.351), B.1.35 of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) - South African variant 501Y.V2 lineage(B.1.351), B.1.351S501Y.V2 lineage(B.1.351)

Reference:
1 Houriiyah Tegally, E. W., Marta Giovanetti, Arash Iranzadeh, Vagner Fonseca, Jennifer Giandhari, Deelan Doolabh, Sureshnee Pillay, Emmanuel James San, Nokukhanya Msomi, Koleka Mlisana, Anne von Gottberg, Sibongile Walaza, Mushal Allam, Arshad Ismail, Thabo Mohale, Allison J Glass, Susan Engelbrecht, Gert Van Zyl, Wolfgang Preiser, Francesco Petruccione, Alex Sigal, Diana Hardie, Gert Marais, Marvin Hsiao, Stephen Korsman, Mary-Ann Davies, Lynn Tyers, Innocent Mudau, Denis York, Caroline Maslo, Dominique Goedhals, Shareef Abrahams, Oluwakemi Laguda-Akingba, Arghavan Alisoltani-Dehkordi, Adam Godzik, Constantinos Kurt Wibmer, Bryan Trevor Sewell, José Lourenço, Luiz Carlos Junior Alcantara, Sergei L Kosakovsky Pond, Steven Weaver, Darren Martin, Richard J Lessells, Jinal N Bhiman, Carolyn Williamson, View ORCID ProfileTulio de Oliveira. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv preprint, doi:https://doi.org/10.1101/2020.12.21.20248640 (2020).